Doxorubicin-Induced Cardiomyopathy Latest Advances
Find the Latest Research About Doxorubicin-Induced Cardiomyopathy
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1565 publications
Multiomics Analysis Reveals the Protective Effect of a Novel Bioactive Peptide (BP1) in Cardiomyopathy Using a Zebrafish Model.
Journal: Journal of proteome research
Published: April 14, 2026
EVs-Mediated Intracardiac Crosstalk Mitigates Doxorubicin-Induced Cardiotoxicity.
Journal: Circulation research
Published: April 08, 2026
Cysteine imaging reveals early redox dysregulation and identifies gnetol as a ferroptosis-modulating agent in doxorubicin cardiotoxicity.
Journal: Redox biology
Published: March 04, 2026
Targeted nano delivery of p53 DNA and carvedilol for the treatment of dilated cardiomyopathy in a rat model.
Journal: Nanomedicine (London, England)
Published: February 25, 2026
Molecular Insights into Doxorubicin-Induced Cardiotoxicity and Phytochemical-Based Cardioprotection: Challenges and Future Strategies.
Journal: Drug metabolism reviews
Published: February 10, 2026
Molecular insights into doxorubicin-induced cardiotoxicity and phytochemical-based cardioprotection: challenges and future strategies.
Journal: Drug metabolism reviews
Published: February 10, 2026
Gain-of-Function Variant TRPC6 A404V Is Associated With Doxorubicin-Related Cardiomyopathy.
Journal: Circulation. Genomic and precision medicine
Published: January 28, 2026
Ubiquitin-specific protease 20(USP20) mitigates doxorubicin-induced cardiotoxicity by deubiquitinating and stabilizing HuR.
Journal: International journal of biological macromolecules
Published: January 13, 2026
Functional Evaluation of TRPC6 Missense Variants in Cancer Patients via Molecular Docking Analysis Compared with Patch Clamp Electrophysiology.
Journal: bioRxiv : the preprint server for biology
Published: January 09, 2026
Meta-analysis of genome-wide association studies of doxorubicin-induced arrhythmia identifies MMP16 and KCTD15 as risk loci.
Journal: medRxiv : the preprint server for health sciences
Published: December 25, 2025
Reversible Heart Failure After Anthracycline and Alkylating Agent Chemotherapy.
Journal: Cureus
Published: December 24, 2025
GSK-3α activation mitigates Doxorubicin-induced cardiomyopathy through Keap1/Nrf2/HO-1 axis.
Journal: Life sciences
Published: December 22, 2025
Last Updated: 04/28/2026